NVO vs SGMT
NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access. SGMT: Sagimet Biosciences is a clinical-stage biotech developing oral FASN inhibitors to treat metabolic dysfunction-associated steatohepatitis (MASH) and other metabolic diseases.
Side-by-side fundamentals
| Metric | NVO | SGMT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $48.19 | $7.05 | |
| Market cap as of 2026-07-23 | $219.8B | $431M | |
| P/E as of 2026-07-23 | 11.78 | n/a | |
| PEG as of 2026-07-23 | 16.16 | n/a | |
| Net margin as of 2026-07-23 | +37.2% | -1393.8% | NVO higher |
| Gross margin as of 2026-07-23 | +81.8% | n/a | |
| Operating margin as of 2026-07-23 | +45.3% | -1537.0% | NVO higher |
| ROE as of 2026-07-23 | +66.4% | -37.6% | NVO higher |
| ROA as of 2026-07-23 | +23.3% | -35.5% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.00 | SGMT lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.1% | n/a | |
| Dividend yield as of 2026-07-23 | +3.7% | n/a | |
| Beta as of 2026-07-23 | 1.85 | 3.45 | |
| 1-year return as of 2026-07-22 close | -23.8% | -26.6% | NVO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.